Siligmueller & Norvid Wealth Advisors’s Perspective Therapeutics CATX Stock Holding History

Siligmueller & Norvid Wealth Advisors’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$565K	Buy	+164,711	New	+$600K	0.25%	74

Other funds holding CATX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NWMG

Nicholson Wealth Management Group Charlestown, South Carolina $172M AUM 10.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Siligmueller & Norvid Wealth Advisors's CATX Position: Q3 2025 in Review

Siligmueller & Norvid Wealth Advisors opened a new position in Perspective Therapeutics (CATX) in Q3 2025: 164,711 shares worth $565K. The stake represents 0.25% of the portfolio and ranks #74 among its holdings.

105 funds tracked by Wall St. Rank hold CATX as of Q3 2025.

Siligmueller & Norvid Wealth Advisors held 164,711 shares of Perspective Therapeutics worth $565K as of Q3 2025.
Perspective Therapeutics was a new Siligmueller & Norvid Wealth Advisors position in Q3 2025.
Perspective Therapeutics made up 0.25% of Siligmueller & Norvid Wealth Advisors's portfolio in Q3 2025, its #74 holding.
105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2025.

Based on Siligmueller & Norvid Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.